Stock Market News
Allergy Therapeutics' latest data highlights benefits of adjuvant technology
Commercial biotechnology firm Allergy Therapeutics on Monday published new data highlighting its technology's effectiveness as an adjuvant compared to existing treatments.
According to Allergy Therapeutics, the study data published highlights the company's microcrystalline tyrosine (MCT) as a suitable and flexible alternative to aluminium hydroxide in allergen specific immunotherapy and infectious disease applications.
Matthias Kramer, Allergy Therapeutics' international medical director and co-author of the paper, said: "These findings provide evidence of the effectiveness of MCT as an adjuvant, confirming the mechanism of action underlying its ability to induce a robust and sustained immunological response. Additionally, the findings indicated a potentially favourable profile for the use of MCT over alum in allergy-specific vaccines."
Adjuvants stimulate an immune response to antigens and allow the body to rapidly respond to threats.
"We believe these data highlight the significance of our differentiated proprietary platform technology in the development of our growing suite of cutting-edge, globally marketed ultra-short course allergy vaccines," said Kramer.
Additionally, the company is currently undergoing studies with a cancer (melanoma) model.
As of 1337 BST, Allergy Therapeutics' shares were up 3.16% at 24.50p.
According to Allergy Therapeutics, the study data published highlights the company's microcrystalline tyrosine (MCT) as a suitable and flexible alternative to aluminium hydroxide in allergen specific immunotherapy and infectious disease applications.
Matthias Kramer, Allergy Therapeutics' international medical director and co-author of the paper, said: "These findings provide evidence of the effectiveness of MCT as an adjuvant, confirming the mechanism of action underlying its ability to induce a robust and sustained immunological response. Additionally, the findings indicated a potentially favourable profile for the use of MCT over alum in allergy-specific vaccines."
Adjuvants stimulate an immune response to antigens and allow the body to rapidly respond to threats.
"We believe these data highlight the significance of our differentiated proprietary platform technology in the development of our growing suite of cutting-edge, globally marketed ultra-short course allergy vaccines," said Kramer.
Additionally, the company is currently undergoing studies with a cancer (melanoma) model.
As of 1337 BST, Allergy Therapeutics' shares were up 3.16% at 24.50p.
Related share prices |
---|
Allergy Therapeutics (AGY) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price